AB SCIEX, Prosolia enter technology license agreement

Prosolia, Inc. and AB SCIEX announced today that they have entered into a license agreement for technologies developed by Dr. Gary Van Berkel and his colleagues of Oak Ridge National Laboratory (ORNL).  Dr. Van Berkel is an innovator in the field of mass spectrometry and is the recipient of several awards for his contributions in the field.  The agreement provides Prosolia a license to a portfolio of new sample introduction and ionization methods based on the liquid micro- junction surface sampling probe approach that enables direct extraction of solid-phase analytes from a variety of surfaces using a continuous flow of solvent.  Its advantages provide research scientists and technicians access to rapid sample analyses in combination with multi-modal ionization capabilities and the versatility of coupling to thin-layer and liquid chromatography techniques.

"Our agreement with AB SCIEX further strengthens our position as the leader in ambient ionization mass spectrometry systems," said Justin Wiseman, President and CEO of Prosolia.  "Prosolia's growing patent portfolio is strong and is a critical element to our business strategy. We envision several new products arising out of Dr. Van Berkel's inventions and are excited to work with him and his group on these projects." 

Prosolia is a scientific instrument company developing and marketing novel research tools for scientists and technicians in academic, government, pharmaceutical, clinical and forensics research laboratories.  Their products streamline analytical workflows

The flagship product for Prosolia is based on the Desorption Electrospray Ionization (DESI) technology.   DESI enables rapid spot sampling and chemical imaging of surfaces under ambient conditions using mass spectrometry.  Their current products retro-fit onto instruments produced by the major instrument companies including AB SCIEX, Thermo Scientific, Waters, Agilent, Bruker and LECO Corp.

"We are delighted that our collaboration with thought leaders at Oak Ridge National Laboratory continues to be validated by the growing interest across the life science industry," said Dave Hicks, Vice President of the Pharma and Academic Business, AB SCIEX.  "Licensing the technology to other companies such as Prosolia will help speed up the commercialization of this novel sampling innovation."

Source:

Prosolia, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2019, June 20). AB SCIEX, Prosolia enter technology license agreement. News-Medical. Retrieved on October 15, 2024 from https://www.news-medical.net/news/20120522/AB-SCIEX-Prosolia-enter-technology-license-agreement.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "AB SCIEX, Prosolia enter technology license agreement". News-Medical. 15 October 2024. <https://www.news-medical.net/news/20120522/AB-SCIEX-Prosolia-enter-technology-license-agreement.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "AB SCIEX, Prosolia enter technology license agreement". News-Medical. https://www.news-medical.net/news/20120522/AB-SCIEX-Prosolia-enter-technology-license-agreement.aspx. (accessed October 15, 2024).

  • Harvard

    Thermo Fisher Scientific Inc.. 2019. AB SCIEX, Prosolia enter technology license agreement. News-Medical, viewed 15 October 2024, https://www.news-medical.net/news/20120522/AB-SCIEX-Prosolia-enter-technology-license-agreement.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Thermo Fisher Scientific and Symphogen extend collaboration to boost drug discovery and development